A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension
Hypertension

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Blood Pressure, Hypertension, Cortisol
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of hypertension with blood pressure ≥ 140/90 millimeters of mercury (mmHg) and < 180/110 mmHg on current antihypertensive treatment
- Male and female participants 18-75 years of age
- Participants must weigh at least 50 kilograms (kg)
Exclusion Criteria:
- Recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebral accident or transient ischemic attack
- Clinically significant electrocardiography (ECG) findings related to cardiac conduction defects
- Type 1 diabetes or uncontrolled type 2 diabetes (haemoglobin A1c [HbA1c] > 9%)
- Malignancies within the last 5 years (excluding basal cell skin cancer)
- Liver disease
Other protocol-defined inclusion/exclusion criteria may apply.
Sites / Locations
- Impact Clinical Trials
- Associated Pharmaceutical Research Center, Inc
- Innovative Clinical Research, Inc
- Long Beach Center for Clinical Research
- Metro Clinical Research
- Clinical Study Center of Asheville, LLC
- Northstate Clinical Research
- Tipton Medical & Diagnostic Center
- Punzi Medical Center
- dgd Research, Inc
- Encode Clinic
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
Cohort A: LCI699 0.5 mg QD
Cohort A: LCI699 1.0 mg QD
Cohort B1: LCI699 1.0 mg BID
Cohort B1: LCI699 2.0 mg QD
Placebo
Participants received LCI699 0.5 mg, capsules, orally, once daily (QD), with or without food for up to 6 weeks.
Participants received LCI699 1.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
Participants received LCI699 1.0 mg, capsules, orally, twice daily (BID), with or without food for up to 6 weeks.
Participants received LCI699 2.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
Participants received LCI699-matching placebo, capsules, orally, QD or BID, with or without food for up to 6 weeks.